Montag A & Associates Inc. Boosts Holdings in Bristol-Myers Squibb (NYSE:BMY)

Montag A & Associates Inc. raised its position in Bristol-Myers Squibb (NYSE:BMY) by 319.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 89,258 shares of the biopharmaceutical company’s stock after acquiring an additional 67,966 shares during the period. Montag A & Associates Inc.’s holdings in Bristol-Myers Squibb were worth $5,048,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Roxbury Financial LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $60,000. Covenant Asset Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $279,000. Spinnaker Trust raised its position in Bristol-Myers Squibb by 7.5% in the fourth quarter. Spinnaker Trust now owns 16,033 shares of the biopharmaceutical company’s stock worth $907,000 after acquiring an additional 1,113 shares in the last quarter. Bank Pictet & Cie Europe AG acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at $13,094,000. Finally, Valeo Financial Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 8.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 53,919 shares of the biopharmaceutical company’s stock worth $3,050,000 after purchasing an additional 4,186 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Down 3.8 %

Shares of NYSE BMY opened at $53.85 on Friday. The firm’s 50 day moving average price is $57.21 and its 200 day moving average price is $54.07. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The firm has a market cap of $109.22 billion, a P/E ratio of -12.18, a price-to-earnings-growth ratio of 2.13 and a beta of 0.45. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.75 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were given a $0.62 dividend. The ex-dividend date was Friday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.61%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BMY. Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their price target for the company from $55.00 to $73.00 in a report on Tuesday, November 12th. Citigroup boosted their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Morgan Stanley raised their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th. Finally, Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $57.86.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.